Author

Kendelle Joan Murphy

Garvan Institute of Medical ResearchORCID 0000-0002-3234-3812Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Max NobisiD· 3 shared Paul TimpsoniD· 3 shared Thomas R. CoxiD· 3 shared Alice M. H. Tran· 2 shared Anaiis Zaratzian· 2 shared Andrew Da Silva· 2 shared Anna E. HowelliD· 2 shared Anthony James GilliD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Max NobisORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJul 23, 2026

Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer

Kendelle Joan Murphy, Cecilia R. Chambers, Daniel A. Reed…·Paul Timpson

This paper shows that pulsed narmafotinib priming improves chemotherapy response in pancreatic cancer by reducing fibrosis and enhancing treatment efficacy.

DOI 10.64898/2026.07.23.740234

humanexperimental assay

𝕏 PostBluesky

Cell BiologybioRxivPreprintJul 21, 2025

ROCK2 inhibition has a dual role in reducing ECM remodelling and cell growth, while impairing migration and invasion

Daniel A. Reed, Anna E. Howell, Nadia Kuepper…·David Herrmann

This paper shows that ROCK2 inhibition reduces ECM remodelling and cell growth while impairing migration and invasion in breast cancer models.

DOI 10.1101/2025.07.21.666015

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 16, 2025

A selective inhibitor of oncogenic JNK signalling perturbs metastatic outgrowth of triple-negative breast cancer through metabolic blockade

Sharissa L. Latham, Yolande E. I. O’Donnell, Oscar Girgis-Cook…·David R. Croucher

The paper identifies a selective JNK inhibitor that blocks metastasis in triple-negative breast cancer by targeting metabolic pathways.

DOI 10.1101/2025.04.16.649243

humanproteomics

𝕏 PostBluesky